TickerFacts.

Nexalin Technology, Inc. (NXL): Revenue

Annual figures by period end, from SEC filings.

$301.6K
Year ended 2025-12-31
$217.2K
Trailing 12 months to 2026-06-30
-38.9%
3-year compound annual growth
$1.32M2021-12-31: $144.1K2022-12-31: $1.32M2023-12-31: $110.7K2024-12-31: $168.7K2025-12-31: $301.6K$301.6K
2021-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$301.6K+78.8%2026-03-25, From 2025-01-01
2024-12-31$168.7K+52.3%2026-03-25, From 2024-01-01
2023-12-31$110.7K-91.6%2025-09-23, From 2023-01-01
2022-12-31$1.32M+817.2%2024-03-27, From 2022-01-01
2021-12-31$144.1Kn/a2023-03-27, From 2021-01-01

Revenue at similar companies

Companies with the same SEC industry code (Electromedical & Electrotherapeutic Apparatus), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Nexalin Technology, Inc. (NXL)2025-12-31$301.6K+78.8%
Positron Corp (POSC)2025-12-31$461.5K-21.5%
iTonic Holdings Ltd (ITOC)2025-12-31$523.0K+16.7%
Guided Therapeutics Inc (GTHP)2025-12-31$767.0Kn/m
Hongchang International Co., Ltd (HCIL)2024-12-31$2.87M+7.1%
ADM Tronics Unlimited, Inc. (ADMT)2026-03-31$3.35M+4.7%
Neuraxis, Inc (NRXS)2025-12-31$3.57M+32.9%
Yubo International Biotech Ltd (YBGJ)2025-12-31$12.4K+256.0%
Nuwellis, Inc. (NUWE)2025-12-31$8.27M-5.4%

Compare NXL, POSC, ITOC, GTHP side by side · Screen every company in Electromedical & Electrotherapeutic Apparatus ↗